Intersect ENT Inc (XENT)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Intersect ENT Inc (XENT) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011076
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intersect ENT Inc (Intersect), formerly Sinexus Inc is a medical device company that provides chronic sinusitis solutions. The company offers steroid releasing implants and mini steroid implants. It provides surgical solutions for patients, disease recurrence with recurrent symptoms. Intersect develops sinus drug delivery technology. Intersect’s products are used in chronic sinusitis treatment such as facial pain or pressure, nasal congestion and obstruction, loss of smell and taste, headache, discolored nasal discharge, loss of sleep and fatigue and depression. The company also provides treatment through medical therapy and sinus surgery. It distributes its products in domestic and overseas markets. Intersect is headquartered in Menlo Park, California, the US.

Intersect ENT Inc (XENT) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intersect ENT Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Intersect ENT Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Intersect ENT Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Intersect ENT Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Intersect ENT Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Intersect ENT Inc, Medical Equipment, Deal Details 10
Venture Financing 10
Intersect ENT Raises US$30 Million In Series D Financing 10
Intersect ENT Secures An Additional Of US$1.02 Million In Series C Financing 12
Equity Offering 14
Intersect ENT Raises USD103 Million in Public Offering Shares 14
Intersect ENT Raises USD63.3 Million in IPO 16
Intersect ENT Inc – Key Competitors 17
Intersect ENT Inc – Key Employees 18
Intersect ENT Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Nov 02, 2017: Intersect ENT Reports Third Quarter 2017 Results 20
Aug 01, 2017: Intersect ENT Reports Second Quarter 2017 Results 21
May 02, 2017: Intersect ENT Reports First Quarter 2017 Results 22
Feb 28, 2017: Intersect ENT Reports Fourth Quarter and Full Year 2016 Results 23
Jan 09, 2017: Intersect ENT Reports Preliminary Q4 and Year 2016 Revenue 24
Nov 02, 2016: Intersect ENT Reports Third Quarter 2016 Results 25
Aug 02, 2016: Intersect ENT Reports Second Quarter 2016 Results 27
Jul 18, 2016: Intersect ENT Announces Preliminary Q2 Revenue and Business Update 28
May 05, 2016: Intersect ENT Reports First Quarter 2016 Results 29
Feb 23, 2016: Intersect ENT Reports Fourth Quarter and Year 2015 Results 30
Jan 11, 2016: Intersect ENT Reports Preliminary Q4 and Year 2015 Revenue 31
Corporate Communications 32
Jul 20, 2017: Teresa L. Kline Joins Intersect ENT’s Board of Directors 32
Feb 22, 2016: Intersect ENT Appoints David Lehman General Counsel 33
Product News 34
03/23/2016: Intersect ENT Announces FDA Approval Of Additional Indication For PROPEL Mini Sinus Implant 34
01/29/2016: Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany 35
Product Approvals 36
Mar 23, 2016: Intersect ENT Announces FDA Approval Of Additional Indication For PROPEL Mini Sinus Implant 36
Jan 29, 2016: Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Intersect ENT Inc, Medical Equipment, Key Facts, 2016 2
Intersect ENT Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Intersect ENT Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Intersect ENT Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Intersect ENT Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Intersect ENT Inc, Deals By Market, 2011 to YTD 2017 8
Intersect ENT Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Intersect ENT Raises US$30 Million In Series D Financing 10
Intersect ENT Secures An Additional Of US$1.02 Million In Series C Financing 12
Intersect ENT Raises USD103 Million in Public Offering Shares 14
Intersect ENT Raises USD63.3 Million in IPO 16
Intersect ENT Inc, Key Competitors 17
Intersect ENT Inc, Key Employees 18

★海外企業調査レポート[Intersect ENT Inc (XENT)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Marinus Pharmaceuticals Inc (MRNS):企業の財務・戦略的SWOT分析
    Summary Marinus Pharmaceuticals Inc (Marinus) is a clinical stage biopharmaceutical company that manufactures and commercializes therapeutics for the treatment of epilepsy, neuropsychiatric disorders and others diseases. The company’s pipeline product comprise ganaxolone is a CNS-selective GABAA mod …
  • Sabre Corp (SABR):企業の財務・戦略的SWOT分析
    Sabre Corp (SABR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Ubisoft Entertainment S.A.:企業の戦略・SWOT・財務分析
    Ubisoft Entertainment S.A. - Strategy, SWOT and Corporate Finance Report Summary Ubisoft Entertainment S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • McKinsey & Company, Inc.:企業の戦略・SWOT・財務情報
    McKinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary McKinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Charles River Laboratories International Inc (CRL):医療機器:M&Aディール及び事業提携情報
    Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. Th …
  • Ford Motor Company:企業の戦略・SWOT・財務情報
    Ford Motor Company - Strategy, SWOT and Corporate Finance Report Summary Ford Motor Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Carpenter Co:企業の戦略的SWOT分析
    Carpenter Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Gilead Sciences Inc (GILD):医療機器:M&Aディール及び事業提携情報
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency …
  • SPI Energy Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Spi Energy Co Ltd (Spi Energy), formerly Solar Power Inc, is a photovoltaic (PV) solutions provider. The company offers development, financing, installation, operation and sale of utility-scale and residential solar power projects. It also operates online energy e-commerce and investment pla …
  • Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報
    Summary Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG …
  • DPL Inc:企業の戦略的SWOT分析
    DPL Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Bank Audi S.A.L.:戦略・SWOT・企業財務分析
    Bank Audi S.A.L. - Strategy, SWOT and Corporate Finance Report Summary Bank Audi S.A.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Pakistan Petroleum Ltd (PPL):企業の財務・戦略的SWOT分析
    Pakistan Petroleum Ltd (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Glanbia Nutritionals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Glanbia Nutritionals Inc (Glanbia Nutritionals) is a global provider of nutritional ingredients, functional ingredients, and customized premix solutions. The company manufactures and markets customized micronutrient blends, vitamins, minerals, amino acids, colors and specialty ingredients. T …
  • Atopix Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Atopix Therapeutics Ltd (Atopix) is a clinical stage biotechnology company that develops novel treatments for Th2-mediated eosinophilic asthma. The company’s product portfolio includes CRTH2 used in the treatment of atopic dermatitis. It also offers ATX2417 and OC459 used in treatment of ast …
  • PPL Corp (PPL):企業の財務・戦略的SWOT分析
    PPL Corp (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • American Bridge Company:企業の戦略・SWOT・財務情報
    American Bridge Company - Strategy, SWOT and Corporate Finance Report Summary American Bridge Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Wayne State University:製薬・医療:M&Aディール及び事業提携情報
    Summary Wayne State University (WSU) is a public research university that offers academic and certificate programs for graduates and undergraduates. The university offers academic programs such as business, engineering, information science, arts and sciences, law, medicine, nursing and health scienc …
  • Navigator Holdings Ltd (NVGS):企業の財務・戦略的SWOT分析
    Summary Navigator Holdings Ltd (Navigator) operates as an oil and gas company that offers seaborne transportation of liquefied gases. The company transports ammonia, ethane, ethylene, ambient LPG, petrochemicals and LPG products. It provides fleet management, ship management, gas transportation and …
  • International Drug Development Institute-製薬・医療分野:企業M&A・提携分析
    Summary International Drug Development Institute (IDDI) is a healthcare institute that offers clinical data collection, analysis, trial design and trial reporting services. The institute offers biostatistical services and eClinical services and risk-based monitoring programs. Its biostatistical and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆